

### AHCCCS Clinical Criteria Changes: High-Cost Oral Atypical Antipsychotics

AHCCCS routinely updates its pharmacy clinical criteria and prior authorization guidance. The High-Cost Atypical Oral Antipsychotics (HCAOA), currently include Caplyta, Fanapt, Lybalvi, Rexulti and Vraylar.

The changes are summarized in the table below:

FDA Indication	Current Criteria	New Criteria	Summary of Changes
<b>Schizophrenia</b> (Caplyta, Fanapt, Lybalvi, Rexulti and Vraylar)	4 steps of either oral or injectable antipsychotics  For Lybalvi, also a trial of olanzapine	2 trials of oral atypical antipsychotics*  For Lybalvi, BMI parameters	<b>Reduction of 2-3 steps</b>
<b>Bipolar I Disorder</b> (Fanapt, Lybalvi and Vraylar)	3 steps through mood stabilizers and 3 steps through atypical antipsychotics.	3 trials through mood stabilizers/atypical antipsychotics*  For Lybalvi, BMI parameters	<b>Reduction of 3 steps</b>
<b>Bipolar Depression</b> (Caplyta and Vraylar)	4 steps through mood stabilizers/atypical antipsychotics	3 trials through mood stabilizers/atypical antipsychotics*	<b>Reduction of 1 step</b>
<b>Major Depressive Disorder (MDD)</b> (Rexulti and Vraylar)	For MDD 3 steps through antidepressants and 3 steps through atypical antipsychotics	Trials of 2 medications from 2 different antidepressant therapeutic classes* and inadequate response to two atypical antipsychotics*	<b>Reduction of 2 steps</b>
<b>Treatment Resistant Depression</b> (Vraylar)	Not previously in criteria		
<p>*Upon publication, PA Guidelines will have further details and medication/criteria specifics.  <i>Note:</i> As with AHCCCS' previous criteria, members may also be approved for these medications if they are newly enrolled and currently on the requested medication or if they are currently receiving treatment with the requested medication in the hospital and must continue upon discharge.</p>			

Several additional changes, including a new indication for Rexulti (agitation associated with Alzheimer's Disease), as well as quantity limits, are detailed in the clinical criteria. New branded oral agents will be added to this criteria as they become available, as appropriate.

More information, and detailed clinical criteria will also be posted on the [AHCCCS Pharmacy Website](#).